Bulk Pharmaceutical API Sources for QUETIAPINE FUMARATE

Bulk Pharmaceutical API Sources for QUETIAPINE FUMARATE

Vendor	Vendor Homepage	Vendor Sku	API Url
NIH Clinical Collection		SAM001246777
NIH Clinical Collection		SAM001247041
Hangzhou Trylead Chemical Technology		TL8000348
NovoSeek		5281025
NovoSeek		6918224
ZINC		ZINC19632628

Bulk API Sources for Quetiapine Fumarate

Last updated: February 5, 2026

The global supply of quetiapine fumarate API (Active Pharmaceutical Ingredient) depends on manufacturing capacity, quality compliance, and regional approvals. Several large-scale manufacturers dominate the market, supplemented by smaller producers and custom synthesis options.

---

Major API Manufacturers and Suppliers

Company Name	Location	Market Share	Notable Certifications	Production Capacity (est.)	Notes
Teva Pharmaceutical Industries	Israel	Estimated 35%	GMP, ISO 9001, ISO 14001	High, multiple facilities	One of the largest producers; supplies globally
Mylan (now part of Viatris)	USA	Estimated 20%-25%	GMP, ISO 9001	Large, multiple sites	Extensive distribution network
Sandoz (Novartis)	Switzerland	Estimated 15%-20%	GMP, ISO 9001	Significant, multiple plants	Mainly supplies Europe and US markets
Jiangsu Hengrui Medicine	China	Approx. 10%	GMP, ISO 9001	Growing capacity	Focus on Asian markets, expanding globally
Other regional suppliers	Various	Remaining share	GMP	Variable, generally smaller	Some regional suppliers operate under CDMO arrangements

Note: Exact market share figures are proprietary but based on industry reports such as IQVIA and PharmSource[1].

---

Regional API Sources

• United States: Mylan, Anchen Pharmaceuticals, and several CDMOs supply API complying with FDA standards.
• Europe: Sandoz and Teva dominate with GMP-compliant manufacturing; several smaller European companies also produce API under European Medicines Agency (EMA) approval.
• China: Jiangsu Hengrui, Zhejiang NHU, and others supply both domestic and export markets; China’s API exports face regulatory scrutiny under international standards.
• India: Multiple API producers operate under European and US certifications; companies like Torrent Pharmaceuticals and Emcure produce API for export markets.

---

Cost and Quality Considerations

• Quality Standards: Suppliers must adhere to GMP and often ISO 9001. Qualified suppliers hold valid drug master files and may have USFDA or EMA inspections.

• Cost Factors: Prices range depending on capacity, certification, and contractual volume. US/EU suppliers tend to command premium prices due to stringent regulatory compliance.

• Supply Chain Risks: Political/regulatory changes, customs tariffs, and geopolitical issues influence supply reliability. Multiple sourcing strategies mitigate risks.

---

Supply Chain Challenges

• Manufacturing Congestion: Global COVID-19 disruptions have led to bottlenecks in API production, including for quetiapine fumarate.

• Regulatory Hurdles: Import/export regulations, especially for Chinese and Indian API, influence timelines and costs. Suppliers often require detailed validation and documentation.

• Intellectual Property: Quetiapine fumarate patents have expired in many jurisdictions, opening markets to multiple generic suppliers. This reduces API costs but raises quality control considerations.

---

Custom and Contract API Manufacturing

• Several CDMOs (Contract Development and Manufacturing Organizations) provide custom synthesis services, including high-purity API suitable for generic formulations[2].

• Companies such as AstraZeneca, Dr. Reddy's, Biocon, and others operate API production lines for quetiapine fumarate, often under licensing agreements or third-party procurement.

---

Future Outlook

• API supply is likely to diversify further due to capacity expansions in China and India.

• Regulatory pressures aim to improve API quality and traceability, especially in the US and EU markets.

• Price competition may compress margins, encouraging innovation in production efficiencies.

---

Key Takeaways

• Multiple major suppliers globally—Teva, Mylan, Sandoz—control substantial market share.
• Chinese and Indian manufacturers are significant API sources with expanding capacities.
• Quality compliance (GMP, ISO) remains crucial for market acceptance.
• Supply chain risks related to geopolitical and regulatory environments persist.
• Contract manufacturing organizations represent flexible sources for high-purity API production.

---

FAQs

Q1: Who are the leading suppliers of quetiapine fumarate API?

A1: Teva, Mylan (Viatris), Sandoz, and Jiangsu Hengrui are predominant suppliers offering high-volume, GMP-compliant API.

Q2: How does the quality regulation differ between regions?

A2: US and European suppliers typically adhere to more stringent GMP standards regulated by the FDA and EMA, respectively. Chinese and Indian suppliers may have varying compliance levels but increasingly seek international certifications.

Q3: What are the main challenges in sourcing quetiapine fumarate API?

A3: Challenges include regulatory hurdles, supply chain disruptions, capacity limitations, and maintaining consistent quality standards across regions.

Q4: Are there regional differences in API pricing?

A4: Yes; prices are generally higher in Western markets due to regulatory compliance costs, while Chinese and Indian suppliers often offer more competitive prices, subject to quality verification.

Q5: What future trends could affect the API supply landscape?

A5: Capacity expansion in Asia, tightening of quality regulations, and supply chain diversification efforts are likely to influence the API sourcing options for quetiapine fumarate.

---

References

[1] IQVIA Institute. "The Global Use of Medicine," 2022.
[2] PharmSource. "CDMO API Manufacturing Trends," 2021.